Live Breaking News & Updates on அஜி உயிர் பார்மா

Stay updated with breaking news from அஜி உயிர் பார்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study


(1)
SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ Ajinomoto Bio-Pharma Services ( Aji Bio-Pharma ), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ( Humanigen ), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab, today announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is one of the few Phase 3 treatment options in development for patients hospitalized with COVID-19.
Aji Bio-Pharma will assume a key role in simplifying the supply chain efforts for Humanigen by providing drug product aseptic fill finish services at its San Diego facility to support continued clinical trial efforts through potential commercialization. Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazi ....

San Diego , United States , Cameron Durrant , Kristin Defife , Operations Site Head At Ajinomoto Bio Pharma Services , Exchange Commission , Gilead Company , Humanigen Inc , Prnewswire Ajinomoto Bio Pharma Services Aji , Ajinomoto Bio Pharma Services , Bio Pharma Services , Use Authorization , Aji Bio Pharma , Chief Executive Officer , Site Head , Ajinomoto Bio Pharma , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , கேமரூன் ட்யுரெஂட் , செயல்பாடுகள் தளம் தலை இல் அஜினோமோடோ உயிர் பார்மா சேவைகள் , பரிமாற்றம் தரகு , கிலியட் நிறுவனம் , அஜினோமோடோ உயிர் பார்மா சேவைகள் , உயிர் பார்மா சேவைகள் , பயன்பாடு அங்கீகாரம் , அஜி உயிர் பார்மா ,

Recro Announces Executive Changes


Recro Announces Executive Changes
David Enloe Named President and Chief Executive Officer
December 16, 2020 07:00 ET
| Source:
Recro Pharma, Inc.
Recro Pharma, Inc.
Malvern, Pennsylvania, UNITED STATES
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today.
Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CD ....

United States , San Diego , Bryan Lake , David Enloe , David Rosen , Sam Martin Claudia Styslinger , Wayneb Weisman , Gerri Henwood , Bachelor Of Business Administration , Company Board Of Directors , Baudax Bio Inc , Arthur Andersen Co , Exchange Commission , Recro Pharma Inc , University Of Texas At Austin , Securities Exchange , Ajinomoto Bio Pharma Services , Chief Executive Officer , Aji Bio Pharma , Baudax Bio , San Diego Business , Viral Therapeutics Business Unit , Preceding Vivante , Introgen Therapeutics , Senior Vice President , Business Administration ,